Loss of function of NF1 is a mechanism of acquired resistance to endocrine therapy in lobular breast cancer-Reference-Cited by-同舟云学术

Loss of function of NF1 is a mechanism of acquired resistance to endocrine therapy in lobular breast cancer

Published:2019-01 Issue:1 Volume:30 Page:115-123
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Sokol E.S.,Feng Y.X.,Jin D.X.,Basudan A.,Lee A.V.,Atkinson J.M.,Chen J.,Stephens P.J.,Frampton G.M.,Gupta P.B.,Ross J.S.,Chung J.H.,Oesterreich S.,Ali S.M.,Hartmaier R.J.

Funder

ILC

BCRF

Susan G Komen Leadership Award

Metastatic Breast Cancer Network

National Institute of General Medical Sciences

National Institutes of Health

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/30/1/115/27511340/mdy497.pdf

Reference30 articles.

1. Invasive lobular carcinoma of the breast: response to hormonal therapy and outcomes;Rakha;Eur J Cancer,2008

2. Invasive lobular carcinoma of the breast: patient response to systemic endocrine therapy and hormone response in model systems;Sikora;Steroids,2013

3. Relative effectiveness of letrozole compared with tamoxifen for patients with lobular carcinoma in the BIG 1-98 Trial;Metzger Filho;JCO,2015

4. Activating ESR1 mutations in hormone-resistant metastatic breast cancer;Robinson;Nat Genet,2013

5. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer;Toy;Nat Genet,2013

Cited by 61 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. NF1 deficiency drives metabolic reprogramming in ER+ breast cancer;Molecular Metabolism;2024-02

2. Co-regulator activity of Mediator of DNA Damage Checkpoint 1 (MDC1) is associated with DNA repair dysfunction and PARP inhibitor sensitivity in lobular carcinoma of the breast;2023-10-30

3. NF1 alterations in cancers: therapeutic implications in precision medicine;Expert Opinion on Investigational Drugs;2023-10-03

4. Frequency of genetic alterations differs in advanced breast cancer between metastatic sites;Genes, Chromosomes and Cancer;2023-09-06

5. Genomic Alterations Associated with Estrogen Receptor Pathway Activity in Metastatic Breast Cancer Have a Differential Impact on Downstream ER Signaling;Cancers;2023-09-04